AZ Will Sideline ‘Lucky Mistake’ To Secure COVID-19 Vaccine Approval
US Unlikely To Accept Data
Executive Summary
A lower first dose boosted the vaccine’s efficacy result – but AstraZeneca has conceded this has to be proven in a separate trial.
You may also be interested in...
UK Authorizes ‘Gamechanger’ AstraZeneca Vaccine Despite Data Doubts
UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.
UK Authorizes ‘Gamechanger’ AstraZeneca Vaccine Despite Data Doubts
UK regulator admits evidence sparse on older patients, but believes longer gap between doses can boost efficacy and accelerate numbers of people immunized.
Oxford’s Vaccine Results Still Puzzle, AZ Expects Not To File With FDA
Partners hope non-US regulators will authorize early and then await later readouts to clarify vaccine's profile, but FDA is expected to hold out for US trial data.